Title |
Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells
|
---|---|
Published in |
Archivum Immunologiae et Therapiae Experimentalis, February 2018
|
DOI | 10.1007/s00005-018-0507-9 |
Pubmed ID | |
Authors |
Zohreh Sadat Badieyan, Sayed Shahabuddin Hoseini |
Abstract |
Cancer has been ranked as the second leading cause of death in the United States. To reduce cancer mortality, immunotherapy is gaining momentum among other therapeutic modalities, due to its impressive results in clinical trials. The genetically engineered T cells expressing chimeric antigen receptors (CARs) are emerging as a new approach in cancer immunotherapy, with the most successful outcomes in the refractory/relapse hematologic malignancies. However, the widespread clinical applications are limited by adverse effects some of which are life-threatening. Strategies to reduce the chance of side effects as well as close monitoring, rapid diagnosis and proper treatment of side effects are necessary to take the most advantages of this valuable therapy. Here we review the reported toxicities associated with CAR engineered T cells, the strategies to ameliorate the toxicity, and further techniques and designs leading to a safer CAR T-cell therapy. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 30 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 8 | 27% |
Student > Master | 6 | 20% |
Student > Doctoral Student | 4 | 13% |
Student > Ph. D. Student | 3 | 10% |
Other | 2 | 7% |
Other | 2 | 7% |
Unknown | 5 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 5 | 17% |
Agricultural and Biological Sciences | 5 | 17% |
Medicine and Dentistry | 5 | 17% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
Immunology and Microbiology | 2 | 7% |
Other | 3 | 10% |
Unknown | 7 | 23% |